This study revealed a dual pharmacological mechanism by which AF-SD treats ROU: (i) suppression of pro-inflammatory cytokines and (ii) promotion of angiogenesis and tissue repair via VEGF upregulation. Here, VEGFA is linked to atrial fibrillation.